Herantis Pharma Oyj

Equities

HRTIS

FI4000087861

Biotechnology & Medical Research

Market Closed - Nasdaq Helsinki Other stock markets 16:07:32 04/06/2024 BST			5-day change	1st Jan Change
1.535 ^EUR	-7.25%		-5.25%	-2.54%

05-20	Herantis Pharma Submits Clinical Trial Application for A Phase 1B Clinical Trial of Her-096	CI
03-06	Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

October 30, 2020 at 04:00 pm

Herantis Pharma Plc announced Ingrid Heiman's decision to step down from her role in Herantis' Board of Directors effective immediately. Ingrid Heiman's tenure in Herantis' Board of Directors commenced in the extraordinary general meeting held in the spring of 2019.

Latest news about Herantis Pharma Oyj

Herantis Pharma Submits Clinical Trial Application for A Phase 1B Clinical Trial of Her-096	05-20	CI
Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024	03-06
Transcript : Herantis Pharma Oyj - Special Call	25/10/23
Herantis Pharma's Early-stage Study of Parkinson's Therapy Shows Positive Data; Stock Surges	25/10/23	MT
Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096	25/10/23	CI
Herantis Pharma Secures EUR4.5 Million Loan Waive-off From Business Finland	25/09/23	MT
Transcript : Herantis Pharma Oyj, H1 2023 Earnings Call, Aug 24, 2023	24/08/23
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study	22/08/23	CI
Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096	04/07/23	CI
Herantis Pharma Doses First Patient in Phase 1 Trial for Parkinson's Disease Therapy	19/04/23	MT
Herantis Pharma Oyj Announces First Healthy Volunteer Dosed in the Phase 1a Clinical Study for the Parkinson's Disease Drug Candidate, HER-096	19/04/23	CI
Transcript : Herantis Pharma Oyj, H2 2022 Earnings Call, Mar 02, 2023	02/03/23
Herantis Pharma Shares Surge on Approval of Clinical Trial Application For Parkison's Disease Treatment	20/02/23	MT
Herantis Pharma plc Announces Approval of Clinical Trial Application for A Phase 1 Study for HER-096	20/02/23	CI
Transcript : Herantis Pharma Oyj - Special Call	19/01/23
Herantis Pharma Oyj Announces Submission of A Clinical Trial Application for A Phase 1 Study for HER-096	19/12/22	CI
Herantis Pharma Secures Nasdaq Stockholm's Approval for Delisting	05/12/22	MT
Finland's Herantis Pharma Applies to Cancel Secondary Listing on Nasdaq First North Growth Market Sweden	01/12/22	MT
Herantis Pharma plc Announces Appointments to Shareholders' Nomination Committee	26/10/22	CI
Transcript : Herantis Pharma Oyj, H1 2022 Earnings Call, Aug 25, 2022	25/08/22
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Herantis Pharma plc Announces Executive Changes	08/07/22	CI
Herantis Pharma Says Trial Results Support Development of Neurodegenerative Diseases Treatment	28/04/22	MT

Chart Herantis Pharma Oyj

Duration

Period

More charts

Company Profile

Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinsonâs disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HERANTIS PHARMA OYJ	-2.54%	36.32M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	121B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.82B
ARGENX SE	+1.69%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-40.52%	16.33B
BEIGENE, LTD.	-14.00%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.74B

Bio Therapeutic Drugs